Prostate health index density in the diagnosis of clinically significant prostate cancer in equivocal magnetic resonance imaging of the prostate in the Taiwan community

Prostate Health Index Density in the diagnosis of Clinically significant prostate cancer in PI-RADS 3 of prostate mpMRI in the Taiwan community

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN66525057

Enrollment

450

Registered

2024-03-05

Start date

2016-04-01

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer screening Cancer

Interventions

This is a multicenter study of Taiwan men with PHI and MRI-targeted and systematic prostate biopsies performed. From 2016 to 2022, after obtaining informed consent, we enrolled patients who were more

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients who were more than 40 years old and underwent MRI-targeted prostate biopsy for suspicious PCa due to elevated serum PSA level (PSA > 4 ng/mL)

Exclusion criteria

Exclusion criteria: Prostate malignancy diagnosed before

Design outcomes

Primary

Measure	Time frame
Prostate cancer measured using the pathology report taken at a single time point.	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Taiwan

Contacts

Public ContactChing-hsin Chang

123001@h.tmu.edu.tw+886-2-2737-2181

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026